Sign in

    SamPiper Sandler

    Sam's questions to Regeneron Pharmaceuticals Inc (REGN) leadership

    Sam's questions to Regeneron Pharmaceuticals Inc (REGN) leadership • Q4 2024

    Question

    Sam, on behalf of Christopher Raymond at Piper Sandler, asked about the pricing strategy for EYLEA following a modest price increase, and whether the goal is to stabilize the average sale price.

    Answer

    CEO Dr. Leonard Schleifer and EVP of Commercial Marion McCourt both declined to comment on pricing strategy. McCourt clarified that a modest price increase was applied to EYLEA HD.

    Ask Fintool Equity Research AI